Alnylam Pharmace. buy Stifel Nicolaus
Start price
27.06.24
/
50%
€228.70
Target price
27.06.25
€275.15
Performance (%)
1.31%
Price
05.07.24
€231.70
Summary
This prediction is currently active. With a performance of 1.31%, the BUY prediction by Stifel_Nicolaus for Alnylam Pharmace. is trending in the right direction. This prediction currently runs until 27.06.25. The prediction end date can be changed by Stifel_Nicolaus at any time. Stifel_Nicolaus has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w |
|---|---|
| Alnylam Pharmace. | 2.115% |
| iShares Core DAX® | 1.395% |
| iShares Nasdaq 100 | 2.287% |
| iShares Nikkei 225® | 1.617% |
| iShares S&P 500 | 0.659% |
Comments by Stifel_Nicolaus for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Stifel Nicolaus from $215.00 to $295.00. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Stopped prediction by Stifel_Nicolaus for Alnylam Pharmace.
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€181.40
14.09.23
14.09.23
€225.00
14.09.24
14.09.24
27.73%
05.07.24
05.07.24
